2024
Efficacy And Safety Of Sacubitril/valsartan In Patients Hospitalized With Heart Failure: A Prespecified, Pooled Individual Patient-level Analysis Of PIONEER-HF And PARAGLIDE-HF
Morrow D, Velazquez E, Desai A, DeVore A, Lepage S, Park J, Sharma K, Solomon S, Starling R, Ward J, Williamson K, Zieroth S, Hernandez A, Mentz R, Braunwald E. Efficacy And Safety Of Sacubitril/valsartan In Patients Hospitalized With Heart Failure: A Prespecified, Pooled Individual Patient-level Analysis Of PIONEER-HF And PARAGLIDE-HF. Journal Of Cardiac Failure 2024, 30: 312-313. DOI: 10.1016/j.cardfail.2023.10.467.Peer-Reviewed Original ResearchSacubitril/valsartanPIONEER-HFHeart failurePooled analysisNT-proBNPControl therapyDe novo heart failurePlasma NT-proBNP levelsIndependent clinical events committeeIndividual patient-level analysisNovo heart failureNT-proBNP levelsClinical events committeePatient-level analysisCardiovascular deathHemodynamic stabilizationPrimary endpointSymptomatic hypotensionRenal functionMedian ageClinical outcomesRandomized trialsClinical effectsEvents committeeHF events
2018
A meta‐analysis of MitraClip combined with medical therapy vs. medical therapy alone for treatment of mitral regurgitation in heart failure patients
Giannini C, D'ascenzo F, Fiorelli F, Spontoni P, Swaans MJ, Velazquez EJ, Armeni P, Adamo M, De Carlo M, Petronio AS. A meta‐analysis of MitraClip combined with medical therapy vs. medical therapy alone for treatment of mitral regurgitation in heart failure patients. ESC Heart Failure 2018, 5: 1150-1158. PMID: 30191666, PMCID: PMC6300824, DOI: 10.1002/ehf2.12339.Peer-Reviewed Original ResearchConceptsFunctional mitral regurgitationMedical therapyMitral regurgitationSurvival benefitConservative treatmentPercutaneous mitral valve repairEffect of MitraClipRobust survival benefitSignificant survival benefitCardiac resynchronization therapyEligible observational studiesHeart failure patientsVentricular ejection fractionMitral valve repairPatient-level analysisComprehensive literature searchStudy-level analysisConservative therapyIschemic etiologyPrimary endpointFailure patientsMultivariate adjustmentEjection fractionResynchronization therapySurvival outcomes